SYDNEY, Jan. 7, 2022 /PRNewswire/ -- Kazia
Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused
drug development company, is pleased to announce that CEO, Dr
James Garner, will be speaking at
the HC Wainwright BioConnect Conference, to be held virtually from
10-13 January 2022. The company has
been invited to participate via a 'fireside chat' with a senior
equity research analyst at the bank.
The HC Wainwright BioConnect Conference brings together more
than 275 presenting companies from the life sciences sector, along
with invited speakers and panellists. This year's keynote speakers
include Scott Gottlieb, MD, who was
Commissioner of the Food and Drug Administration (FDA) between 2017
and 2019.
Dr Garner will participate in a fireside chat with Sean Lee, an equity research analyst at HC
Wainwright. Dr Garner's interview will be available via online
streaming at the conference event platform from 7am (ET) on
Monday, January 10, 2022. The
interview is expected to cover an update on Kazia's significant
progress in 2021, and a discussion of the rich milestones
anticipated in 2022.
Registration to the conference is free and is available via the
conference website at:-
https://hcwevents.com/bioconnect/
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an
oncology-focused drug development company, based in Sydney, Australia.
Our lead program is paxalisib, a brain-penetrant inhibitor of
the PI3K / Akt / mTOR pathway, which is being developed to treat
glioblastoma, the most common and most aggressive form of primary
brain cancer in adults. Licensed from Genentech in late 2016,
paxalisib commenced recruitment to GBM AGILE, a pivotal study in
glioblastoma, in January 2021. Eight
additional studies are active in various forms of brain cancer.
Paxalisib was granted Orphan Drug Designation for glioblastoma by
the US FDA in February 2018, and Fast
Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted
Rare Pediatric Disease Designation and Orphan Designation by the US
FDA for DIPG in August 2020.
Kazia is also developing EVT801, a small-molecule inhibitor of
VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to
be active against a broad range of tumour types and has provided
compelling evidence of synergy with immuno-oncology agents. A phase
I study commenced recruitment in November
2021.
For more information, please visit www.kaziatherapeutics.com or
follow us on Twitter @KaziaTx.
This document was authorized for release to the ASX by
James Garner, Chief Executive
Officer, Managing Director.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kazia-therapeutics-to-present-at-hc-wainwright-bioconnect-conference-301455376.html
SOURCE Kazia Therapeutics Limited